These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976 [TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. Lin CC; Gray PJ; Jemal A; Efstathiou JA J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435 [TBL] [Abstract][Full Text] [Related]
26. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Foster CC; Jackson WC; Foster BC; Johnson SB; Feng FY; Hamstra DA Radiat Oncol; 2014 Nov; 9():245. PubMed ID: 25424123 [TBL] [Abstract][Full Text] [Related]
27. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Wilkins AC; Gusterson B; Szijgyarto Z; Haviland J; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley DP; Hall E; Somaiah N; Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):309-315. PubMed ID: 29559283 [TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518 [TBL] [Abstract][Full Text] [Related]
29. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531 [TBL] [Abstract][Full Text] [Related]
30. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942 [TBL] [Abstract][Full Text] [Related]
31. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. Patel MA; Kollmeier M; McBride S; Gorovets D; Varghese M; Chan L; Knezevic A; Zhang Z; Zelefsky MJ Radiother Oncol; 2019 Nov; 140():34-40. PubMed ID: 31177042 [TBL] [Abstract][Full Text] [Related]
32. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149 [TBL] [Abstract][Full Text] [Related]
33. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214 [TBL] [Abstract][Full Text] [Related]
34. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. Jackson WC; Suresh K; Tumati V; Allen SG; Dess RT; Salami SS; George A; Kaffenberger SD; Miller DC; Hearn JWD; Jolly S; Mehra R; Hollenbeck BK; Palapattu GS; Schipper M; Feng FY; Morgan TM; Desai NB; Spratt DE Eur Urol; 2018 Oct; 74(4):413-419. PubMed ID: 29306514 [TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831 [TBL] [Abstract][Full Text] [Related]
36. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. Mason MD; Parulekar WR; Sydes MR; Brundage M; Kirkbride P; Gospodarowicz M; Cowan R; Kostashuk EC; Anderson J; Swanson G; Parmar MK; Hayter C; Jovic G; Hiltz A; Hetherington J; Sathya J; Barber JB; McKenzie M; El-Sharkawi S; Souhami L; Hardman PD; Chen BE; Warde P J Clin Oncol; 2015 Jul; 33(19):2143-50. PubMed ID: 25691677 [TBL] [Abstract][Full Text] [Related]
37. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473 [TBL] [Abstract][Full Text] [Related]
38. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043 [TBL] [Abstract][Full Text] [Related]
39. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605 [TBL] [Abstract][Full Text] [Related]
40. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]